Figures & data
Figure 1 Model structure.
![Figure 1 Model structure.](/cms/asset/a1067791-c0b9-4836-a084-80d28e7c44c4/dceo_a_12162217_f0001_c.jpg)
Table 1 Market Share With And Without Uptake Of Avelumab As 2L Therapy
Table 7 Results Of Sensitivity Analyses – Budget Impact Over 3-Year Time Horizon
Table 2 Dosing, Duration, Drug And Administration Costs
Table 3 Percentage Of Patients Experiencing Grade ≥3 Adverse Events And Total Adverse Event Costs
Table 4 Healthcare Resource Costs Of Adverse Event Management
Table 5 Disease Management Costs
Figure 2 Budget impact of avelumab in the treatment of locally advanced or mUC (A) Commercial perspective and (B) Medicare perspective (US$).
![Figure 2 Budget impact of avelumab in the treatment of locally advanced or mUC (A) Commercial perspective and (B) Medicare perspective (US$).](/cms/asset/103a86fc-06d9-4f58-b98e-e23a49b9ca87/dceo_a_12162217_f0002_c.jpg)
Table 6 Budget Impact Over 3-Year Time Horizon